社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
WengYongLi
Wander beyond the wilderness
IP属地：未知
+关注
帖子 · 175
帖子 · 175
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
WengYongLi
WengYongLi
·
2021-12-24
Pfizer will continue to soar short term. There are so little competition for vaccines.
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>
Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for
How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>
看
2,202
回复
1
点赞
1
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-12-15
Very insightful especially on crypto’s topic.
非常抱歉，此主贴已删除
看
2,715
回复
1
点赞
1
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-12-11
Its more than what meets the headlines. China is always cautious. But good for long run
非常抱歉，此主贴已删除
看
2,766
回复
1
点赞
3
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-11-17
Who cares what bofa says. They only care about their own bags
Sea shares fell more than 7% in morning trading<blockquote>Sea股价早盘下跌超7%</blockquote>
Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth. Bank of America analys
Sea shares fell more than 7% in morning trading<blockquote>Sea股价早盘下跌超7%</blockquote>
看
2,608
回复
评论
点赞
4
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-11-12
Slow but sure
看
2,535
回复
评论
点赞
4
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-11-10
As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued
非常抱歉，此主贴已删除
看
2,809
回复
1
点赞
7
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-11-09
$Iveda Solutions, Inc.(IVDA)$
Up only
看
2,778
回复
评论
点赞
1
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-11-07
$Booking Holdings(BKNG)$
This has been on meteoric rise. Once gantry all open, price goes up another 30%
看
2,491
回复
评论
点赞
3
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-11-03
$Iveda Solutions, Inc.(IVDA)$
slow and sure
看
2,752
回复
评论
点赞
3
编组 21备份 2
分享
举报
WengYongLi
WengYongLi
·
2021-10-20
$4DS Memory(4DS.AU)$
Hidden and suspended
看
2,220
回复
评论
点赞
3
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574715322913604","uuid":"3574715322913604","gmtCreate":1611622781309,"gmtModify":1628260964620,"name":"WengYongLi","pinyin":"wengyongli","introduction":"","introductionEn":"","signature":"Wander beyond the wilderness","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":26,"headSize":134,"tweetSize":175,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.24","exceedPercentage":"80.09%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":698360236,"gmtCreate":1640306326685,"gmtModify":1640306391646,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"Pfizer will continue to soar short term. There are so little competition for vaccines. ","listText":"Pfizer will continue to soar short term. There are so little competition for vaccines. ","text":"Pfizer will continue to soar short term. There are so little competition for vaccines.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698360236","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=zh_CN&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b> announced Wednesday its oral COVID-19 antiviral pill, <b>Paxlovid,</b> has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布推出口服COVID-19抗病毒药物，<b>帕克斯洛维德、</b>已被美国授权使用。食品和药物管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of <b>Merck & Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应使辉瑞占据主导市场地位：</b>辉瑞公司提前获得了口服COVID-19治疗的认可<b>默克公司。</b>Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote></p><p> The drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid应该仍然是稳定的贡献者：</b>美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b> Pfizer shares closed lower 1.41% to $58.71 on Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?<blockquote>辉瑞的口服COVID-19药丸能带来多少收入？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-24 07:26</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><b>Pfizer, Inc.</b> announced Wednesday its oral COVID-19 antiviral pill, <b>Paxlovid,</b> has been authorized for use by the U.S. Food and Drug Administration.</p><p><blockquote><b>辉瑞公司。</b>周三宣布推出口服COVID-19抗病毒药物，<b>帕克斯洛维德、</b>已被美国授权使用。食品和药物管理局。</blockquote></p><p> <b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p><p><blockquote><b>辉瑞分析师：</b>SVB Leerink分析师Geoffrey Porges给予辉瑞市场表现评级和52美元的目标价。</blockquote></p><p> BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p><p><blockquote>美银证券分析师Geoff Meacham维持中性评级和59美元的目标价。</blockquote></p><p> <b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of <b>Merck & Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p><p><blockquote><b>广泛的标签，增加供应使辉瑞占据主导市场地位：</b>辉瑞公司提前获得了口服COVID-19治疗的认可<b>默克公司。</b>Porges在一份报告中表示，该公司比辉瑞公司提前一个多月提交了molnupiravir的申请。</blockquote></p><p> The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p><p><blockquote>该分析师认为，辉瑞明年Paxlovid的预期供应量增加至1.2亿个疗程意义重大。该分析师表示，该公司将销售和分销其中大部分课程，其收入将远远超过SVB Leerink目前预测的2022年Paxlovid销售额240亿美元和2023年330亿美元。</blockquote></p><p> Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p><p><blockquote>该分析师表示，2024年收入贡献将降至100亿美元。他补充说，预计2022-24年Paxlovid总销售额为670亿美元，远高于共识。</blockquote></p><p> The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p><p><blockquote>Porges说，药物间相互作用对Paxlovid摄取的影响不大，因为清单上的许多药物可以在Paxlovid治疗的短期内暂停，而不会对患者产生重大影响。他补充说，可能被排除在Paxlovid使用之外的患者是那些患有严重肝或肾功能损害的患者以及那些HIV-1感染未得到控制的患者。</blockquote></p><p> The drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p><p><blockquote>分析师表示，该药物标签也没有排除孕妇接受Paxlovid治疗，并且与默克公司的molnupiravir相比，其风险/益处相对良性，后者显示了动物的胚胎发育和胎儿生长风险。</blockquote></p><p> Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p><p><blockquote>Paxlovid比一些领先的抗体疗法具有更好的疗效，并且由于一些抗体疗法已经失去了针对奥密克戎病毒变异体的疗效，Paxlovid将是“对医生和患者来说非常有吸引力的选择”，Porges说。</blockquote></p><p> <b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p><p><blockquote><b>美国银行表示，Paxlovid应该仍然是稳定的贡献者：</b>美国银行分析师米查姆表示，到2022年销售辉瑞生产的每一个疗程的Paxlovid应该没有问题。他补充说，生产和运输/收入确认之间的滞后时间意味着辉瑞不会在2022年确认每剂疫苗的收入。</blockquote></p><p> Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p><p><blockquote>分析师表示，从长远来看，Paxlovid可能仍然是一个稳定的贡献者。</blockquote></p><p> \"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p><p><blockquote>“我们预计突破性感染将在流行阶段定期继续，虽然疫苗和先前感染的基线免疫力水平将限制严重程度，但我们预计在高危个体中发生的新冠病例的治疗将成为标准护理，”米查姆说。</blockquote></p><p> Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p><p><blockquote>分析师表示，预计政府实体将储备默克的药物，因此初步销售可能会出现。他补充说，从长远来看，Paxlovid可能是首选药物。</blockquote></p><p> <b>Pfizer Price Action:</b> Pfizer shares closed lower 1.41% to $58.71 on Thursday.</p><p><blockquote><b>辉瑞价格走势：</b>辉瑞股价周四收盘下跌1.41%，至58.71美元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2202,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607706537,"gmtCreate":1639583446503,"gmtModify":1639583446829,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"Very insightful especially on crypto’s topic. ","listText":"Very insightful especially on crypto’s topic. ","text":"Very insightful especially on crypto’s topic.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607706537","repostId":"2191956629","repostType":4,"isVote":1,"tweetType":1,"viewCount":2715,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605510379,"gmtCreate":1639189290601,"gmtModify":1639189434109,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"Its more than what meets the headlines. China is always cautious. But good for long run","listText":"Its more than what meets the headlines. China is always cautious. But good for long run","text":"Its more than what meets the headlines. China is always cautious. But good for long run","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605510379","repostId":"2190275356","repostType":4,"isVote":1,"tweetType":1,"viewCount":2766,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878809285,"gmtCreate":1637162516571,"gmtModify":1637162516688,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"Who cares what bofa says. They only care about their own bags","listText":"Who cares what bofa says. They only care about their own bags","text":"Who cares what bofa says. They only care about their own bags","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/878809285","repostId":"1191602151","repostType":4,"repost":{"id":"1191602151","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637160729,"share":"https://www.laohu8.com/m/news/1191602151?lang=zh_CN&edition=full","pubTime":"2021-11-17 22:52","market":"us","language":"en","title":"Sea shares fell more than 7% in morning trading<blockquote>Sea股价早盘下跌超7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1191602151","media":"Tiger Newspress","summary":"Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.\n\nBank of America analys","content":"<p>Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.</p><p><blockquote>美国银行因增长放缓而将Sea股价下调至中性后，Sea股价下跌超过7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b220c8739f206a6f035287f0bc93429\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Bank of America analyst Sachin Salgaonkar downgrades the stock to a Neutral rating from a Buy.</p><p><blockquote>美国银行分析师Sachin Salgaonkar将该股评级从买入下调至中性。</blockquote></p><p> In addition, Sea kept gaming guidance unchanged, which implies slowing growth in Q4, Salgaonkar writes in a note to clients.</p><p><blockquote>此外，Salgaonkar在给客户的一份报告中写道，Sea保持游戏指引不变，这意味着第四季度增长放缓。</blockquote></p><p> The analyst sees a balanced risk/reward for the stock; shares climb 85% Y/Y.</p><p><blockquote>分析师认为该股的风险/回报平衡；股价同比上涨85%。</blockquote></p><p> \"We cut our gaming revenue estimates to factor in a slowdown and increase e-com losses as we factor increasing cash-burn,\" the analyst notes.</p><p><blockquote>分析师指出：“我们下调了游戏收入预期，以考虑到经济放缓和电子商务亏损增加的因素，因为我们考虑到现金消耗增加。”</blockquote></p><p> Lowers full-year 2022 loss per share estimate to $5.72 and 2023 to $4.45 per share.</p><p><blockquote>将2022年全年每股亏损预期下调至5.72美元，将2023年全年亏损预期下调至每股4.45美元。</blockquote></p><p> \"Consensus is yet to factor in rising losses in the medium term based on expansion into new markets in Europe/India.\"</p><p><blockquote>“共识尚未考虑到基于向欧洲/印度新市场扩张的中期亏损上升。”</blockquote></p><p> The Neutral rating agrees theNeutral Quant Rating, with the best factor grade in Momentum and the worst in Valuation.</p><p><blockquote>中性评级与中性量化评级一致，动量因素等级最好，估值最差。</blockquote></p><p> However, the Neutral rating diverges from the Very BullishWall Street Analyst Rating(18 Very Bullish, 7 Bullish).</p><p><blockquote>然而，中性评级与非常看涨的华尔街分析师评级（18非常看涨，7看涨）不同。</blockquote></p><p> Previously, (June 10) Sea gotupgraded to Buy at BofA.</p><p><blockquote>此前，（6月10日）美国银行将Sea评级上调至买入。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6013b61a037fd78ec0a89cb8d3193ddc\" tg-width=\"726\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea shares fell more than 7% in morning trading<blockquote>Sea股价早盘下跌超7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea shares fell more than 7% in morning trading<blockquote>Sea股价早盘下跌超7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-17 22:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.</p><p><blockquote>美国银行因增长放缓而将Sea股价下调至中性后，Sea股价下跌超过7%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4b220c8739f206a6f035287f0bc93429\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Bank of America analyst Sachin Salgaonkar downgrades the stock to a Neutral rating from a Buy.</p><p><blockquote>美国银行分析师Sachin Salgaonkar将该股评级从买入下调至中性。</blockquote></p><p> In addition, Sea kept gaming guidance unchanged, which implies slowing growth in Q4, Salgaonkar writes in a note to clients.</p><p><blockquote>此外，Salgaonkar在给客户的一份报告中写道，Sea保持游戏指引不变，这意味着第四季度增长放缓。</blockquote></p><p> The analyst sees a balanced risk/reward for the stock; shares climb 85% Y/Y.</p><p><blockquote>分析师认为该股的风险/回报平衡；股价同比上涨85%。</blockquote></p><p> \"We cut our gaming revenue estimates to factor in a slowdown and increase e-com losses as we factor increasing cash-burn,\" the analyst notes.</p><p><blockquote>分析师指出：“我们下调了游戏收入预期，以考虑到经济放缓和电子商务亏损增加的因素，因为我们考虑到现金消耗增加。”</blockquote></p><p> Lowers full-year 2022 loss per share estimate to $5.72 and 2023 to $4.45 per share.</p><p><blockquote>将2022年全年每股亏损预期下调至5.72美元，将2023年全年亏损预期下调至每股4.45美元。</blockquote></p><p> \"Consensus is yet to factor in rising losses in the medium term based on expansion into new markets in Europe/India.\"</p><p><blockquote>“共识尚未考虑到基于向欧洲/印度新市场扩张的中期亏损上升。”</blockquote></p><p> The Neutral rating agrees theNeutral Quant Rating, with the best factor grade in Momentum and the worst in Valuation.</p><p><blockquote>中性评级与中性量化评级一致，动量因素等级最好，估值最差。</blockquote></p><p> However, the Neutral rating diverges from the Very BullishWall Street Analyst Rating(18 Very Bullish, 7 Bullish).</p><p><blockquote>然而，中性评级与非常看涨的华尔街分析师评级（18非常看涨，7看涨）不同。</blockquote></p><p> Previously, (June 10) Sea gotupgraded to Buy at BofA.</p><p><blockquote>此前，（6月10日）美国银行将Sea评级上调至买入。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/6013b61a037fd78ec0a89cb8d3193ddc\" tg-width=\"726\" tg-height=\"279\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191602151","content_text":"Sea shares fell more than 7% after cut to Neutral at BofA on slowing growth.\n\nBank of America analyst Sachin Salgaonkar downgrades the stock to a Neutral rating from a Buy.\nIn addition, Sea kept gaming guidance unchanged, which implies slowing growth in Q4, Salgaonkar writes in a note to clients.\nThe analyst sees a balanced risk/reward for the stock; shares climb 85% Y/Y.\n\"We cut our gaming revenue estimates to factor in a slowdown and increase e-com losses as we factor increasing cash-burn,\" the analyst notes.\nLowers full-year 2022 loss per share estimate to $5.72 and 2023 to $4.45 per share.\n\"Consensus is yet to factor in rising losses in the medium term based on expansion into new markets in Europe/India.\"\nThe Neutral rating agrees theNeutral Quant Rating, with the best factor grade in Momentum and the worst in Valuation.\nHowever, the Neutral rating diverges from the Very BullishWall Street Analyst Rating(18 Very Bullish, 7 Bullish).\nPreviously, (June 10) Sea gotupgraded to Buy at BofA.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":2608,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879950506,"gmtCreate":1636678186088,"gmtModify":1636678186503,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"Slow but sure","listText":"Slow but sure","text":"Slow but sure","images":[{"img":"https://static.tigerbbs.com/e52eefd34005572c21b56f1d61e84416","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879950506","isVote":1,"tweetType":1,"viewCount":2535,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847953953,"gmtCreate":1636474166866,"gmtModify":1636474167230,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued","listText":"As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued","text":"As long as they filed sec, its not illegal. Honestly, they also think tesla is overvalued","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847953953","repostId":"1127189501","repostType":2,"isVote":1,"tweetType":1,"viewCount":2809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844447839,"gmtCreate":1636455410265,"gmtModify":1636455410730,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>Up only","listText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>Up only","text":"$Iveda Solutions, Inc.(IVDA)$Up only","images":[{"img":"https://static.tigerbbs.com/bda88f3189c5fd0ed8a4f10f2f8daefb","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844447839","isVote":1,"tweetType":1,"viewCount":2778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845392318,"gmtCreate":1636278122906,"gmtModify":1636278123298,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BKNG\">$Booking Holdings(BKNG)$</a>This has been on meteoric rise. Once gantry all open, price goes up another 30%","listText":"<a href=\"https://laohu8.com/S/BKNG\">$Booking Holdings(BKNG)$</a>This has been on meteoric rise. Once gantry all open, price goes up another 30%","text":"$Booking Holdings(BKNG)$This has been on meteoric rise. Once gantry all open, price goes up another 30%","images":[{"img":"https://static.tigerbbs.com/11541445d326f24f9a97852cc9c2ff40","width":"1125","height":"3463"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845392318","isVote":1,"tweetType":1,"viewCount":2491,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841828036,"gmtCreate":1635902291749,"gmtModify":1635902291866,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>slow and sure","listText":"<a href=\"https://laohu8.com/S/IVDA\">$Iveda Solutions, Inc.(IVDA)$</a>slow and sure","text":"$Iveda Solutions, Inc.(IVDA)$slow and sure","images":[{"img":"https://static.tigerbbs.com/246670e66a2812ef5bb140ace806b7e1","width":"1284","height":"2538"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841828036","isVote":1,"tweetType":1,"viewCount":2752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859297292,"gmtCreate":1634697936966,"gmtModify":1634697998804,"author":{"id":"3574715322913604","authorId":"3574715322913604","name":"WengYongLi","avatar":"https://static.tigerbbs.com/47bde0946b4de3845bcba22c002e0cfd","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574715322913604","idStr":"3574715322913604"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/4DS.AU\">$4DS Memory(4DS.AU)$</a>Hidden and suspended","listText":"<a href=\"https://laohu8.com/S/4DS.AU\">$4DS Memory(4DS.AU)$</a>Hidden and suspended","text":"$4DS Memory(4DS.AU)$Hidden and suspended","images":[{"img":"https://static.tigerbbs.com/067201907e9d120e1588dcf17e2a73db","width":"1242","height":"1767"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859297292","isVote":1,"tweetType":1,"viewCount":2220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}